ACRS / Aclaris Therapeutics, Inc. - Insider Trading and Ownership Report - SEC Form 3, 4, 5

Insider Trading Chart

Insider Roster and Profitability Metrics

This table shows the list known insiders, and is generated automatically from filings disclosed to the SEC. In addition to the names, most recent title, and director, officer, or 10% owner designation, we provide the latest disclosed holdings. Additionally, when possible we provide the historical trade performance for the insider. The historical trade performance is a weighted average of the performance of actual open-market purchase transactions made by the insider. For more information on how this is calculated, watch this YouTube webinar.

See our leaderboard of most profitable insider traders.

Report errors via our new Insider Auditing Tool

Track Records of Insider Purchases - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACRS / Aclaris Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical .

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max	Price at Max	Max Profit ($)	Max Return (%)
2024-11-19	Mehra Anand	666,666	2.2500	666,666	2.2500	1,499,998	0	4.5900	1,559,999	104.00
2024-08-05	Leonard Braden Michael	206,025	1.2443	206,025	1.2443	256,357
2024-08-02	Leonard Braden Michael	167,544	1.2916	167,544	1.2916	216,400
2024-07-31	Leonard Braden Michael	100,000	1.3264	100,000	1.3264	132,640
2024-07-30	Leonard Braden Michael	173,730	1.3030	173,730	1.3030	226,370
2024-07-22	Leonard Braden Michael	17,716	1.3297	17,716	1.3297	23,557
2024-07-19	Leonard Braden Michael	6,689	1.3000	6,689	1.3000	8,696
2024-07-18	Leonard Braden Michael	130,317	1.3011	130,317	1.3011	169,555
2024-07-05	Leonard Braden Michael	123,017	1.1489	123,017	1.1489	141,334

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Track Records of Insider Sales - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACRS / Aclaris Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical .

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Min	Price at Min	Max Loss Avoided ($)	Max Loss Avoided (%)
2023-03-03	Monahan Joseph	16,037	12.6342	16,037	12.6342	202,615	255	0.6449	-192,272	-94.90
2023-03-03	Balthaser Kevin	894	12.6281	894	12.6281	11,290
2023-03-03	Walker Neal	30,240	12.6346	30,240	12.6346	382,070
2023-03-02	Monahan Joseph	14,800	12.3665	14,800	12.3665	183,024
2023-03-02	Balthaser Kevin	1,000	12.2890	1,000	12.2890	12,289
2023-03-02	Walker Neal	29,000	12.3651	29,000	12.3651	358,588
2023-02-08	Loerop James	4,267	13.8909	4,267	13.8909	59,272
2022-03-11	Walker Neal	56,303	15.9147	56,303	15.9147	896,045
2022-03-10	Ruffo Frank	12,823	15.5451	12,823	15.5451	199,335

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b5-1 automatic trading plan will have an X in the column marked 10b-5.